Pfizer has sued Novo Nordisk, accusing it of anti-competitive practices in an attempt to take over Metsera, a potential competitor in the obesity treatment market.

Pfizer has announced that it has filed a lawsuit against Novo Nordisk and Metsera, accusing the Danish company of anti-competitive practices aimed at securing a dominant position in the obesity treatment market. Pfizer claims that Novo Nordisk's attempt to acquire Metsera is intended to eliminate a potential competitor. Additionally, Pfizer accuses the majority shareholders of Metsera of conspiracy to undermine its $4.9 billion offer. Metsera has rejected the allegations, stating that Pfizer is trying to obtain the company at a lower price. The legal conflict highlights the intense competition in the field of obesity treatments, a market estimated at over $100 billion. Novo Nordisk has made a $6 billion offer for Metsera, prompting Pfizer to renegotiate the terms. This dispute reflects the huge stakes in the obesity drug market, where Pfizer is seeking to penetrate, facing difficulties in developing its own products.